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New tumour markers are continually discovered in research
laboratories and then clinically evaluated on a small scale. In
the case of positive results, the best of them are commercially
available some time later and join the existing markers, with
a highly variable half-life of interest! However, for the
clinician, it has become very hard to objectively judge and to
rapidly evaluate the performance of new marker(s) compared
to the older ones, in clinical and cost terms.
This article has developed a procedure of evaluation using
receiver operating characteristic (ROC) curve analysis. To
outline the methodology, we first chose breast cancer, the
most frequent among Western women. Secondly, we chose
carcino-embryonic antigen (CEA), an old tumour marker,
and CA 15.3, a more recent tumour-associated antigen, today
considered as an interesting one in this disease (Gosselin et
al., 1988; Jotti et al., 1990).
Knowing that the widest application of tumour markers
has been therapeutic monitoring of cancer (especially in early
detection of recurrence), high sensitivity is hoped for, to
consider a high pretherapeutic serum value as starting value.
The aim of this study was to compare clinical values of CEA
and CA 15.3, evaluated in the same population of women at
different stages of breast cancer.
Blood samples were obtained in 30 healthy control women
and 60 women which histologically confirmed breast car-
cinoma before treatment (37 T2, 15 T3 and 8 T4, according
to Union Internationale Contre le Cancer (UICC) staging).
Sera were rapidly centrifuged and kept at - 80°C until
analysis. We used ELSA-2 CEA° and ELSA-CA 15.3° mono-
clonal immuno-radiometric kits from CIS' Biointernational
(Gif-sur-Yvette, France); all assays were performed in dup-
licate and a control was included in any analysis. Figure 1
summarises our observations.
According to the classical method (mean + 2 standard
deviations of controls), 95th percentile, cut-offs may be
chosen at 3.3 ng ml-' and 20.5 U ml-' for CEA and CA 15.3
respectively; in these conditions, sensitivity (true positive/
(true positive + false negative)) and specificity (true negative/
(true negative + false positive)) were 25, 96.7, 61.7 and
96.7% respectively. When we chose the cut-offs usually
recommended (i.e. 5 ng ml-' and 30 U ml-1), we obtained
15, 100, 28.3 and 100%. Thus, CA 15.3, with a better sen-
sitivity combined with a similar specificity, may be considered
in both cases as being better than CEA. These facts, taking
into account the characteristics of our population, were in
good agreement compared with those detailed in Table I.
However, accurate comparisons were hard to make, because
of lack of information about tumour staging and the great
number of different CEA commercial assays used in these
studies.
These results may evaluate the potential of the marker
inadequately, because they only depended on one cut-off,
statistically or arbitrarily determined. ROC curve analysis
may allow another approach. This describes a set of points
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(1-specificity, sensitivity) for continuous range of cut-off
points. Thus, we can display the whole spectrum and make a
choice of an optimal cut-point (Bamber, 1975; Metz, 1978;
McNeil & Hanley, 1984; Makuch & Muenz, 1987; Zweig &
Robertson, 1987).
With the use of the ROC curve, it is also possible to
describe and compare two or more different diagnostic tests
without the problem of arbitrary individual cut-off values.
The selection of a cut-off value is not necessary and the
diagnostic tests are compared through the entire ROC curve:
when a ROC curve for test A is above the ROC curve for
test B, the true positive rate for test A is greater than the true
positive rate for test B at every false positive rate and thus
test A is superior to test B. So inspection of the curves could
be sufficient. We can also compare them statistically; to
summarise the ROC curve, an index is generally used. The
area under the curve, which is the probability of correctly
ranking a pair of randomly chosen diseased and non-diseased
subjects, is used. The area and its variance could be
estimated in two different ways.
The curve could be fitted and the expected ROC points
follow a straight line on binormal coordinate paper. The
straight line parameters (slope and intercept) could be
estimated from the maximum likelihood technique and the
area derived; thereby, the comparison between two diagnostic
tests, on both their slopes and intercepts simultaneously
could be done using the likelihood ratio.
A second approach, which is non-parametric, is also possi-
ble when continuous data are available. No assumptions on
underlying distribution need be made to obtain area
measurements; Bamber (1975) showed the equivalence
between area under the ROC curve and the Wilcoxon statis-
tics. So the comparison between two ROC curves is allowed
without curve fitting. We chose the latter solution.
Using conventional software, we contrasted controls and
patients serum levels, plotted ROC curves of CEA (method
1) and CA 15.3 (method 2) (Figure 2). The areas under the
two curves (Al, A2) were analysed by the Wilcoxon statistics
(Bamber, 1975), but graphical methods (trapezium, plani-
meter, etc.) gave the same results. A closed form expression
of their standard deviations was provided with standard
deviations of Wilcoxon statistics (Hanley & McNeil, 1982).
For an overall comparison, we took into account that the
same population of controls and patients was evaluated and
used the method suggested by Hanley & McNeil (1983).
Thus, we computed the z ratio which, under null hypothesis,
follows standardisated normal distribution:
A,-A2
Z =
a/ SE,2+ SE22 -2r SE] SE2
where r represents the correlation between areas, owing to
the fact that measures were paired; this coefficient was
derived from Pearson coefficients of correlation between
method 1 and method 2 data (r, for controls and rp for
patients).
We found: A, = 0.892, A2 = 0.664, SE, = 0.033, SE2=
0.056, r,=0.295, rp=0.426, r=0.32, given z=4.13. There-
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Figure Distributions of CEA and CA 15.3 serum levels in controls and patients.
Table I Studies about sensitivity (5) and specificity (s) of CEA and CA 15.3 using different
cut-offs
CEA CA 15.3
Cut-off Cut-off
Study (ngml-') S(Oo) s(0o) (Uml-') S(% s(%)
Pons et at. (1987) 5 25 16.5 (N- 99
54 (N+)
Catarino et at. (1988) 5 10 25 19
lager et at. (1987) 12 6.6 (MO) 25 15.6 (MO) 100
71.4 (M+) 79.7 (M+)
Schmidt-Rhode et at. (1987) 30 23.6 100
Martin et at. (1988) 6 16 (MO) 35 9 (MO)
63 (M+) 90 (M+)
Eskelinen et at. (1989) 3 23 25 28
5 18 35 20
This study 3.3 25 96.7 20.5 61.7 96.7
5 15 100 30 28.3 100
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Figure 2 ROC curves of CEA and CA 15.3; points A and A'
correspond to 3.3 and 5 ngml' CEA cut-offs, B and B' to 20.5
and 30 U ml-' CA 15.3 cut-offs respectively. Cut-offs varied from
the detection limit (0.3ngml-' and 0.2Uml-' respectively) to
the highest value (79.6 ngml-' and 620 U ml-' respectively) with
an increment of 0.1 for both markers, Total area is one unit
square.
fore, the difference between areas under the curves was
different with the significance probability P <0.0001. As the
size of our sample was sufficient, according to Hanley and
McNeil (1982), this method revealed that CA 15.3 determina-
tion was more effective than CEA assay. If the measurement
of multiple markers is not possible and we have to choose,
for cost reasons, between CA 15.3 and CEA, the former is a
better choice. Of course, we have to keep in mind that,
according to the previous studies, a small percentage of
patients are CEA + and CA 15.3 - (6.7% (4/60) are CEA
>Sngml-' and CA 15.3 <30 Uml ' in our work).
We have already used ROC analysis to determine the
optimal cut-off of one test (Cazin et al., 1988). In this paper,
we have extended the application of this method to objec-
tively compare clinical values of several blood tests, more
particularly in the case of tumour markers. The example we
chose, CA 15.3 and CEA, in untreated breast cancer, was not
a new one and the conclusion is already known; we have
only used it to illustrate the method.
In conclusion, we suggest that ROC curve analysis, com-
paring several tests without considering a particular cut-off,
represents a finer and more suitable methodology than other
classical methods. This analysis may be very useful, first to
quickly judge the real value of a new test compared to the
old one(s) and secondly to compare different commercial
assays of the same tumour marker.
This work was supported by grants of the Comites du Nord et du
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